Le Lézard
Classified in: Health
Subject: CCA

Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024


SAN DIEGO, April 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the first quarter 2024 following the close of market on Thursday, May 2, 2024. 

On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Jacob Thaysen, Chief Executive Officer, and Joydeep Goswami, Chief Financial Officer and Chief Strategy and Corporate Development Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. 

Conference Call Details

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, May 2, 2024. Interested parties may access the live teleconference through the Investor Info section of Illumina's website at investor.illumina.com. Alternatively, individuals can access the call by dialing 866.400.0049 or +1.323.701.0225 outside North America, both with Conference ID 9170634. To ensure timely connection, please dial in at least ten minutes before the scheduled start of the call.

A replay of the conference call will be posted on Illumina's website after the event and will be available for at least 30 days following.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter)FacebookLinkedInInstagramTikTok, and YouTube

Investors:
Salli Schwartz
+1.858.291.6421
[email protected]

Media:
David McAlpine
+1.347.327.1336
[email protected] 

SOURCE Illumina, Inc.


These press releases may also interest you

at 16:48
The law firms of Kessler Topaz Meltzer & Check, LLP and Carella, Byrne, Cecchi, Brody & Agnello, P.C. inform current and former SilverScript Part D beneficiaries that the firms have filed a class action lawsuit against CVS Health Corporation,...

at 16:28
The Honourable Soraya Martinez Ferrada, Minister of Tourism and Minister responsible for the Economic Development Agency of Canada for the Regions of Quebec, on behalf of the Honourable François-Philippe Champagne, Minister of Innovation, Science and...

at 16:15
CareDx, Inc. ? The Transplant Companytm ? a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers ? today...

at 16:15
Marcus Powlowski, Member of Parliament for Thunder Bay-Rainy River, on behalf of the Honourable Mark Holland, Minister of Health, will hold a news conference to announce funding to improve palliative care. There will be a media availability...

at 16:05
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of...

at 16:05
Syndax Pharmaceuticals , a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on May 1, 2024 the Company granted inducement awards to purchase up to 100,600 shares of common stock to...



News published on and distributed by: